RESEARCH PAPER

The long-acting β₂-adrenoceptor agonist olodaterol attenuates pulmonary inflammation

Eva Wex¹, Ines Kollak¹, Matthias J Duechs¹, Emmanuel Naline², Lutz Wollin¹ and Philippe Devillier²

¹Respiratory Diseases Research, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, and ²UPRES EA 220 and Clinical Research Department, Foch Hospital, University of Versailles Saint-Quentin, Suresnes, France

BACKGROUND AND PURPOSE

β₂-adrenoceptor agonists are widely used in the management of obstructive airway diseases. Besides their bronchodilatory effect, several studies suggest inhibitory effects on various aspects of inflammation. The aim of our study was to determine the efficacy of the long-acting β₂-adrenoceptor agonist olodaterol to inhibit pulmonary inflammation and to elucidate mechanism(s) underlying its anti-inflammatory actions.

EXPERIMENTAL APPROACH

Olodaterol was tested in murine and guinea pig models of cigarette smoke- and LPS-induced lung inflammation. Furthermore, effects of olodaterol on the LPS-induced pro-inflammatory mediator release from human parenchymal explants, CD11b adhesion molecule expression on human granulocytes TNF-α release from human whole blood and on the IL-8-induced migration of human peripheral blood neutrophils were investigated.

KEY RESULTS

Olodaterol dose-dependently attenuated cell influx and pro-inflammatory mediator release in murine and guinea pig models of pulmonary inflammation. These anti-inflammatory effects were observed at doses relevant to their bronchodilatory efficacy. Mechanistically, olodaterol attenuated pro-inflammatory mediator release from human parenchymal explants and whole blood and reduced expression of CD11b adhesion molecules on granulocytes, but without direct effects on IL-8-induced neutrophil transwell migration.

CONCLUSIONS AND IMPLICATIONS

This is the first evidence for the anti-inflammatory efficacy of a β₂-adrenoceptor agonist in models of lung inflammation induced by cigarette smoke. The long-acting β₂-adrenoceptor agonist olodaterol attenuated pulmonary inflammation through mechanisms that are separate from direct inhibition of bronchoconstriction. Furthermore, the in vivo data suggest that the anti-inflammatory properties of olodaterol are maintained after repeated dosing for 4 days.

Abbreviations

ASM, airway smooth muscle; BAL, bronchoalveolar lavage; COPD, chronic obstructive pulmonary disease; CS, cigarette smoke; LABA, long-acting β₂-adrenoceptor agonist
Introduction

β₂-adrenoceptor agonists are widely used in the treatment of obstructive lung diseases. According to the GOLD guidelines, inhaled long-acting β₂-adrenoceptor agonist (LABAs) are recommended for treatment of patients with chronic obstructive pulmonary disease (COPD) who are symptomatic despite regular use of short-acting β₂-adrenoceptor agonists (Vestbo et al., 2013). Recently, olodaterol, a new LABA with true once-daily dosing, has been developed (Bouyssou et al., 2011). Olodaterol is a potent, enantiomerically pure LABA that induces bronchodilation up to 24 h after dosing in patients with COPD (van Noord et al., 2011). Preclinical in vivo experiments and clinical data further add evidence to the anti-inflammatory capacity of β₂-adrenoceptor agonists. In murine models of LPS-induced pulmonary inflammation, formoterol and salmeterol reduced the recruitment of neutrophils to the lung and inhibited the release of pro-inflammatory mediators (Maris et al., 2004; Bosmann et al., 2012). In a clinical setting, salmeterol reduced the neutrophil influx, neutrophil degranulation and TNF-α release after LPS inhalation in healthy volunteers at a clinically relevant dose (Maris et al., 2005). Furthermore, a meta-analysis revealed that LABAs reduced the frequency of COPD exacerbations (Wang et al., 2012).

Taken together, all this evidence suggests that β₂-adrenoceptor agonists exert inhibitory effects on various aspects of the inflammatory processes that characterize obstructive lung diseases. Therefore, the efficacy of olodaterol to inhibit cell influx in animal models of LPS- and CS-induced pulmonary inflammation was tested. To our knowledge, this is the first published study testing the efficacy of a β₂-adrenoceptor agonist in models of CS-induced lung inflammation. Furthermore, the anti-inflammatory action of olodaterol was also assessed on human peripheral blood cells and pulmonary primary cellular preparations. Our results showed that stimulation of β₂-adrenoceptors with olodaterol prevented airway inflammation induced by different stimuli relevant to human lung disease and that this anti-inflammatory effect was mediated through mechanisms that were distinct from direct inhibition of bronchoconstriction.

Methods

Animal welfare and ethical statement

For mice, animal care and experimental procedures complied with German national guidelines and legal regulations and were approved by the ethical committee Regierungspräsidium Tübingen (Germany) (Permit Nos. 08-005, 12-014 and...
Olodaterol attenuates pulmonary inflammation

12-020). C57BL/6 mice were obtained from Charles River Laboratories (Germany), housed in isolated ventilated cages under a 12 h light-dark cycle and received food and water ad libitum. Experiments using guinea pigs complied with the conditions of the UK Home Office Project Licence No. 30-2072 and were performed at Argenta Discovery 2009 Ltd (Harlow, UK). Dunkin–Hartley guinea pigs were obtained from B&K Universal Limited (UK) and were housed in polycarbonate solid-bottomed cages. Food and water were provided ad libitum. All procedures used were as humane as possible and the description of studies involving animals complied with the recommendations of ARRIVE (Kilkenny et al., 2010; McGrath et al., 2010). A total of 186 animals (136 mice; 50 guinea pigs) were used in the experiments described here.

**Mouse model of CS-induced lung inflammation**

Female C57BL/6 mice were exposed to the mainstream smoke of six cigarettes (Roth-Händle without filters; Badische Tabakmanufaktur Roth-Händle®, Lahr, Germany) on days 1 and 2, and to five cigarettes on days 3 and 4. One hour prior to each CS exposure, animals were exposed for 5 min to an aqueous solution of olodaterol (Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany) aerosolized with a jet nebulizer (Pari Master; Pari GmbH, Starnberg, Germany). Eighteen hours after the last CS exposure, animals were killed and lungs were lavaged. CS exposure, drug inhalation and lavage were performed as detailed elsewhere (Wollin and Pieper, 2010).

**Mouse model of LPS-induced lung inflammation**

Female C57BL/6 mice were exposed to 1 mg·mL⁻¹ of LPS from Escherichia coli serotype O111:B4 (Sigma-Aldrich, St. Louis, MO, USA) in PBS by inhalation for 30 min in a cylindrical 32 L Perspex box using a jet nebulizer. One hour prior to LPS inhalation, animals were treated with olodaterol as described above. Four hours after the LPS exposure, animals were killed and lungs were lavaged as detailed elsewhere (Wollin and Pieper, 2010).

**Guinea pig model of CS-induced lung inflammation**

Female Dunkin–Hartley guinea pigs were exposed individually to the mainstream smoke of nine cigarettes (Marlboro 100) daily for 4 consecutive days. Exposure to the smoke lasted 45 min (flow rate of 100 mL·min⁻¹). Animals received olodaterol intranasally under light anaesthesia, 1 h prior to each CS exposure. Twenty-four hours after the final CS exposure, animals were killed by barbiturate anaesthetic overdose and lungs were lavaged with 4 mL PBS. Total and differential cell counts in the lavage fluid were determined using light microscopy.

**Lung function measurement and acetylcholine-induced bronchoconstriction**

Lung function in female C57BL/6 mice was measured as detailed previously (Wollin and Pieper, 2010). Briefly, olo-
daterol was administered as an aerosol of aqueous solutions at different doses for 5 min. One hour later, mice were anaesthetized by i.p. injection of 60 mg·kg⁻¹ pentobarbital (Narcoren; Merial GmbH, Hallbergmoos, Germany) and 2.5 mg·kg⁻¹ xylazine hydrochloride (Rompun; Bayer Vital GmbH, Leverkusen, Germany) in a volume of 10 mL·kg⁻¹. A tracheal cannula was inserted and connected to an integrated ventilation and lung function measurement device (Scireq flexiVent; Emka Technologies, Paris, France). To prevent spontaneous breathing, the animals received 0.8 mg·kg⁻¹ pancuronium bromide (Pancuronium Inresa, Inresa Arzneimittel GmbH, Freiburg, Germany) by i.v. administration at a volume of 5 mL·kg⁻¹. Ventilation was conducted with 150 breaths min⁻¹, a tidal volume of 6.5 mL·kg⁻¹ and 3 cmH₂O end-expiratory pressure. After ventilation to total lung capacity (30 cmH₂O), baseline airway resistance and compliance were determined. A bolus of acetylcholine (50 μL) was administered intravenously as an aqueous solution at increasing concentrations (50, 100, 200 and 400 μg·mL⁻¹) resulting in doses of 125–1000 μg·kg⁻¹ body weight. Maximal bronchoconstriction within 3 min was determined after each bolus and lungs were ventilated to total lung capacity before applying the next bolus. The AUC of resistance increase between 50 and 400 μg·mL⁻¹ acetylcholine of the placebo group was defined as 100%. Concentration–response curves were calculated using log-linear regression analysis with variable slope.

**Mediator measurement in bronchoalveolar lavage (BAL) supernatant**

Pro-inflammatory mediators in BAL supernatant were measured at Myriad RBM (Austin, TX, USA) using a multiplex immunoassay (RodentMAP v3.0).

**LPS-induced mediator release from human parenchymal explants**

The use of lung tissues resected from patients was approved by the regional investigational review board (CPP Ile de France VIII, France) and written informed consent was obtained from each patient. Human lung parenchyma was obtained from 14 patients (age: 66 ± 3 years; males/females, 7/7; non-smokers: 2; smokers and ex-smokers: 8 and 4; pack years: 44 ± 6) undergoing surgical resection for lung carcinoma and who had not received recent chemo/steroid therapy. The procedure for preparation of lung explants has been described elsewhere (Hackett et al., 2008; Buenestado et al., 2013). Explants (5 fragments of 3–5 mm³, total weight ~50–100 mg) were maintained overnight at 4°C in RPMI supplemented with 2 mM L-glutamine, 100 μg·mL⁻¹ streptomycin and 100 U·mL⁻¹ penicillin. The fragments were distributed into six-well plates and incubated with olodaterol or vehicle (DMSO) for 1 h before LPS stimulation (1 μg·mL⁻¹). The maximal DMSO concentration applied to explants in culture did not exceed 0.01% and did not alter the production of cytokines or TNF-α. After 24 h, supernatants were collected and stored at −80°C. Production of cytokines was measured in medium supernatants with ELISA techniques (R&D Systems, Minneapolis, MN, USA).
CD11b expression and TNF-α release assay using human whole blood

Human whole blood was obtained from healthy adult donors who did not take any medication for at least 10 days before venepuncture. Blood samples were pre-incubated with olodaterol for 30 min at 37°C in the CO2 incubator. Then samples were stimulated with 400 pg·mL−1 LPS at 37°C in the presence of the drug. CD11b expression on granulocytes was determined by FACS using a monoclonal mouse anti-human PE-labelled CD11b/Mac-1 antibody (BD Biosciences, San Jose, CA, USA) after 60 min of LPS stimulation. TNF-α in the supernatant was determined after 4 h of LPS stimulation using a commercially available TNF-α ELISA kit (BD Biosciences, San Diego, CA, USA). To test the efficacy of the β-receptor antagonists, human whole blood was pre-incubated with either 30 nM ICI-118,551 or 100 nM CGP-20712A for 30 min at 37°C before the addition of olodaterol.

Transwell migration experiments

Primary human neutrophils were isolated from peripheral blood, obtained as above (healthy adult donors who did not take any medication for at least 10 days before venipuncture). Different concentrations of IL-8 (Biotrend Chemicals, Destin, FL, USA) were tested to stimulate transwell migration ChemoTx® System; Neuro Probe, Inc., Gaithersburg, MD, USA). Cells were pre-incubated with olodaterol for 30 min at room temperature. Migration was stimulated by addition of 3 nM IL-8 to the lower chamber of the transwell. The number of migrated cells was determined using the CellTiter-Glo Luminescent Cell Viability Assay (Promega Corporation, Madison, WI, USA) after 1 h incubation at 37°C.

Data analysis

All data are presented as mean ± SEM. Statistical differences between groups were analysed by one-way ANOVA, followed by Dunnnett’s multiple comparison test. The mediator release from human parenchymal explants was analysed by Friedman test (non-parametric repeated-measure test), followed by Dunn’s multiple comparisons test. Statistical significance was accepted at P < 0.05. The tests were performed using GraphPad Prism version 6.01 for Windows (GraphPad Software, La Jolla, California, USA; www.graphpad.com).

Materials

ICI-118,551 and CGP-20712A were supplied by Sigma-Aldrich (St. Louis, MO, USA) and SCH-527123 was from Synphabase AG (Pratteln, Switzerland).

Results

Olodaterol attenuates pulmonary neutrophilia and pro-inflammatory mediator release in mouse models of CS- and LPS-induced lung inflammation

To determine the anti-inflammatory potential of olodaterol in a mouse model of CS-induced lung inflammation, mice were exposed to CS on 4 consecutive days and treated with olodaterol aerosol before every smoke exposure. CS exposure led to a prominent neutrophilic pulmonary inflammation (Figure 1). Preventive olodaterol treatment dose-dependently reduced cell counts with a maximal effect at the highest dose of 1.0 mg·mL−1 attenuating the total cell count by 60% and the neutrophilic cell count by 69% (Figure 1A and B).

In the LPS model, mice were first exposed to different doses of aerosolised olodaterol and 1 h later to aerosolised LPS for 30 min. As seen in the CS model, 4 h after LPS inhalation, a prominent neutrophilic inflammatory response was measured in the BAL (Figure 2). Olodaterol dose-dependently reduced the neutrophil influx into the lung with a maximal efficacy of 82% at the highest dose of 1 mg·mL−1 (Figure 2B). To test the hypothesis that olodaterol might reduce the release of pro-inflammatory mediators, thereby attenuating pulmonary cell influx, mediators in the BAL supernatant were determined. The highest dose of 1 mg·mL−1 olodaterol significantly reduced TNF-α, myeloperoxidase (MPO), MMP-9, M-CSF-1, GM-CSF and the chemokine CCL4 by 83, 69, 76, 59,
86 and 86%, respectively, but had no significant effects on the release of IL-1β or of KC, the mouse orthologue of the chemokine CXCL1 (Table 1).

Olodaterol diminishes pulmonary cell influx in a guinea pig model of CS-induced lung inflammation

The anti-inflammatory efficacy of olodaterol was also tested in a guinea pig model of CS-induced pulmonary inflammation to exclude the possibility that the anti-inflammatory mechanism was species-specific. Guinea pigs were exposed to CS on 4 consecutive days and olodaterol was administered intranasally 1 h prior to each CS exposure. CS induced a significant increase in neutrophilic and monocytic cell counts in the BAL of CS-exposed animals (Figure 3). CS increased the total BAL cell count, to about three-fold that from air-exposed animals (Figure 3A). CS induced the most prominent increase in BAL neutrophils (Figure 3B). Treatment with $10\mu$g·kg$^{-1}$ olodaterol markedly reduced the total (Figure 3A) and neutrophil (Figure 3B) cell count. In contrast to the mouse model, monocytic cells were also significantly increased and all three doses of olodaterol reduced the monocytic cell accumulation with a maximal effect at $1\mu$g·kg$^{-1}$ olodaterol (Figure 3C).

Olodaterol inhibits acetylcholine-induced bronchoconstriction in mice

The pharmacologically active dose of olodaterol to induce bronchodilation was determined in a model of acetylcholine-induced bronchoconstriction in mice. Olodaterol dose-dependently induced bronchodilation (Figure 4). Analysis of the data suggested biphasic behaviour with a first plateau at 25% bronchoprotection at a dose of $0.03\text{mg·mL}^{-1}$ and a half-maximal effective concentration (EC$_{50}$) of
Olodaterol attenuates pro-inflammatory mediator release from unstimulated and LPS-stimulated parenchymal explants

To translate our findings to human tissue, the efficacy of olodaterol to inhibit the LPS-induced release of pro-inflammatory mediators from human parenchymal explants was tested. At nanomolar concentrations, olodaterol significantly attenuated the LPS-induced release of TNF-α, CCL4, CCL2 and CXCL9 with a maximal efficacy of 45, 32, 43 and 54% (Figure 5) and significantly reduced the mediator release from non-stimulated lung explants with a maximal efficacy of 46% for TNF-α, 42% for CCL4, 37% for CCL2 and 35% for CXCL9 (data not shown).

Discussion and conclusions

β2-adrenoceptor agonists are widely used in the management of obstructive lung diseases, such as COPD. Besides their bronchodilatory effect, several studies suggest an inhibitory effect on various aspects of inflammation that characterize pulmonary diseases. The aim of our study was to test the novel long-acting β2-adrenoceptor agonist olodaterol in...
models of pulmonary inflammation and to shed light on its potential anti-inflammatory mechanism of action to better understand its mode of action, beyond bronchodilation, in clinical use.

In a first set of experiments, olodaterol was tested in acute models of CS-induced pulmonary inflammation in mice and guinea pigs. To our knowledge, this is the first published study testing a β2-adrenoceptor agonist in in vivo models of CS-induced lung inflammation. In both species, olodaterol dose-dependently and highly significantly inhibited the influx of neutrophils into the lung. Furthermore, olodaterol attenuated the influx of inflammatory cells into the lung in a murine model of LPS-induced pulmonary inflammation. To determine whether the doses used in the inflammation models were relevant with regard to their bronchodilatory efficacy, olodaterol was tested in models of acetylcholine-induced bronchoconstriction in both species. In guinea pigs, olodaterol intratracheally applied, using the Respimat soft mist inhaler, showed full bronchoprotection of 100% at a dose of 3 μg·kg⁻¹ (Bouyssou et al., 2010a). With regard to its anti-inflammatory efficacy, olodaterol highly significantly reduced cell influx into the lung already at the lowest tested dose of 1 μg·mL⁻¹ when applied intranasally, which for neutrophils was numerically, however not significantly, further attenuated up to the highest dose of 10 μg·mL⁻¹. Because the Respimat soft mist inhaler is a device which ensures optimal delivery of the drug to the lung and intranasal dosing probably leads to lower deposition rates in the lung, these data reflect the fact that, in guinea pigs, the anti-inflammatory effect of olodaterol occurs at (or even below) a dose which is relevant in terms of its bronchodilatory capacity.

In mice, β-adrenoceptor-mediated relaxation is attributed predominantly to activation of β1-adrenoceptors and to be only partially mediated via the β2-subtype (Henry and Goldie, 1990; Raemdonck et al., 2012). This might explain the biphasic dose–response curve that was observed in our model of acetylcholine-induced bronchoconstriction in mice. Bronchodilation induced at low doses of olodaterol is probably

---

Figure 5

Effect of olodaterol on LPS-induced cytokine release from human lung parenchymal explants. (A) Levels of TNF-α, (B) CCL4, (C) CCL2 and (D) CXCL9 measured in the supernatant of human lung parenchymal explants stimulated with 1 μg·mL⁻¹ LPS for 24 h. Tissue was incubated with olodaterol for 1 h before and during LPS stimulation. Data shown are means ± SEM (n = 9–14 donors). *P < 0.05, **P < 0.01, ***P < 0.001; significantly different from LPS-stimulated, vehicle-treated tissue.
mediated via $\beta_2$-adrenoceptors, whereas at higher doses bronchodilation might be induced by $\beta_1$-adrenoceptors. This would fit the selectivity profile of olodaterol determined in in vitro experiments which showed a 241 times higher affinity for the human $\beta_2$-adrenoceptor compared with the $\beta_1$-adrenoceptor (Bouyssou et al., 2010a). Our data suggest that in the mouse, the $\beta_2$-adrenoceptor-mediated bronchodilation accounts for $\sim$25% of bronchodilation and that the maximal bronchodilation of $\sim$70% achieved with olodaterol might be the accumulated response of the activation of both $\beta_1$- and $\beta_2$-adrenoceptors. However, to further dissect the precise role of $\beta_1$- and $\beta_2$-adrenoceptor activation on smooth muscle relaxation and inflammation in mice, additional experiments would be necessary.

To further investigate the anti-inflammatory efficacy of olodaterol, pro-inflammatory mediators were measured in the BAL supernatant obtained in the LPS experiment. At 1 mg·mL$^{-1}$, a dose which inhibits the acetylcholine-induced bronchoconstriction by 68% in mice, olodaterol significantly attenuated the levels of TNF-α, MPO, MMP-9, M-CSF-1, GM-CSF and CCL4, adding evidence for anti-inflammatory mechanisms, other than bronchodilation, for olodaterol.

Our in vivo data are in accordance with many in vivo studies demonstrating that short-term treatment with different $\beta_2$-adrenoceptor agonists reduced the cell recruitment and inhibited the release of pro-inflammatory mediators in LPS-induced inflammation models in mice and rats (Izeboud et al., 1999; Shinkai et al., 2003; Maris et al., 2004; Miyamoto et al., 2004; Bosmann et al., 2012). Furthermore, in two clinical settings in healthy volunteers, a single dose of salmeterol or salbutamol reduced the neutrophil influx and TNF-α release after LPS inhalation at a clinically relevant dose (Masclans et al., 1996) and prevented platelet-activating factor-induced pulmonary sequestration of radio-labelled neutrophils (Maris et al., 2005). However, although diverse preclinical and clinical studies have clearly demonstrated the anti-inflammatory efficacy of $\beta_2$-adrenoceptor activation, rapid desensitization of $\beta_2$-adrenoceptors on airway inflammatory cells is often considered a potential pitfall in translating preclinical findings obtained in short-term models into

Figure 6
Effect of olodaterol on CD11b expression, TNF-α release and neutrophil migration. (A) CD11b expression on granulocytes was measured after incubation of human peripheral whole blood with olodaterol for 30 min and subsequently stimulated with 400 pg·mL$^{-1}$ LPS for 1 h in the presence of the drug. CD11b expression was determined by FACS using a monoclonal mouse anti-human PE-labelled CD11b/Mac-1 antibody. (B) TNF-α release was measured after incubation of blood with olodaterol for 30 min and subsequently stimulated with 400 pg·mL$^{-1}$ LPS for 4 h in the presence of the drug. To test the antagonist effects, whole blood was pre-incubated with either ICI-118,551 (open triangles) or CGP-20712A (open squares) for 30 min before the addition of olodaterol (filled circles). (C) Transwell migration of isolated human peripheral blood neutrophils stimulated by different concentrations of IL-8. The number of migrated cells was determined using the CellTiter-Glo luminescent cell viability assay. Generation of the luminescent signal is proportional to the amount of ATP present, which signals the presence of metabolically active cells in the lower compartment. (D) Cells were pre-incubated with olodaterol (filled circles) or the CXCR2 antagonist SCH-527123 (open squares) for 30 min. Migration was stimulated by addition of 3 nM IL-8 to the lower chamber of the transwell. Data shown are means ± SEM ($n$ = 3–4 donors).
clinical situations (Barnes, 1999). In this regard, our data clearly demonstrate that the anti-inflammatory efficacy of olodaterol was shown not only after single dosing (e.g. in the LPS experiment), but was maintained both in mice and guinea pigs, after repetitive dosing for 4 consecutive days in the CS experiments. Thus, our data confirm previous observations and also extend our knowledge by showing that the anti-inflammatory properties of the LABA olodaterol were maintained after repeated dosing. Furthermore, in patients with mild asthma, a 4 week treatment with formoterol significantly reduced sputum IL-8 levels and neutrophil numbers (Maneechotesuwan et al., 2005). Additionally, treatment with salmeterol over a period of 6 weeks decreased the number of neutrophils in bronchial biopsies and MPO levels in serum, adding more evidence for the persistence of the anti-inflammatory efficacy of β2-adrenoceptor agonists, after repeated dosing (Jeffery et al., 2002; Maneechotesuwan et al., 2005).

To test whether our findings from the LPS and CS models did translate to human tissues, the efficacy of olodaterol to inhibit pro-inflammatory mechanisms in human parenchymal explants was determined. Comparable to the data obtained in the BAL fluid from the murine LPS model, olodaterol reduced the LPS-induced release of TNF-α, CCL4, CCL2 and CXCL9 from human parenchymal explants. These data are in agreement with a recent report by Buenestado et al. (2013), demonstrating that increasing cAMP levels in human parenchymal explants using the PDE4 inhibitor rolflumilast attenuated LPS-induced TNF-α and chemokine production. Furthermore, we demonstrate that olodaterol almost completely blocks the LPS-induced TNF-α release from human peripheral whole blood.

Because inflammatory disorders, such as COPD, are characterized by the over-expression of adhesion molecules which lead to the recruitment of leukocytes to the site of inflammation, human peripheral whole blood was stimulated with LPS and the expression of the adhesion molecule CD11b on granulocytes was measured. As expected, LPS induced a concentration-dependent increase in CD11b expression, and olodaterol partly inhibited this increased expression by up to 48% at a concentration of 10⁻⁸ M. These data are in agreement with a study by Profita et al. (2012), demonstrating that olodaterol significantly reduced CD11b expression on human neutrophils which was induced by the incubation of cells with induced sputum supernatants from patients with COPD. Furthermore, other in vitro studies showed that stimulation of β2-adrenoceptors attenuated neutrophil adhesion to the vascular endothelium (Derian et al., 1995; Bolton et al., 1997) and IFN-γ-induced increase in ICAM-1 expression on bronchial epithelial cells (Oddera et al., 1998). However, whether the reduced CD11b expression was due to a direct effect on CD11b synthesis and release, or indirectly through reducing TNF-α expression (which induces CD11b up-regulation) remains to be determined (Diez-Fraile et al., 2000).

Furthermore, in the CD11b and TNF-α assays, we demonstrated that the anti-inflammatory effects of olodaterol were indeed mediated through the β2-receptor because the selective β2-adrenoceptor antagonist ICI-118,551 reduced the potency of olodaterol in inhibiting both the TNF-α release and the CD11b expression. However, the selective β1-adrenoceptor antagonist CGP-20712A had no effect on the potency and maximal efficacy of olodaterol. Because there are conflicting data on whether β2-agonists directly inhibit neutrophil migration, we isolated the primary human neutrophils from peripheral blood, confirmed the expression of functional β2-adrenoceptors by performing cAMP assays, and stimulated transwell migration with human IL-8. Olodaterol had no effect on the transwell migration of human neutrophils up to a concentration of 10⁻⁷ M, which is compatible with the results of Strandberg et al. (2010) who showed that formoterol did not affect IL-8-induced migration of human peripheral blood neutrophils.

In conclusion, in the present study, we have demonstrated the anti-inflammatory activity of the novel once-daily LABA olodaterol in different preclinical models of COPD in mice and guinea pigs. This provides the first evidence for anti-inflammatory activity of a β2-adrenoceptor agonist in in vivo models of CS-induced lung inflammation. Furthermore, our study demonstrated that the anti-inflammatory effect was mediated through additional mechanisms that were separate from direct inhibition of bronchoconstriction and that even repetitive treatment with olodaterol on 4 consecutive days inhibited cell influx into the lung. Mechanistically, olodaterol inhibited release of pro-inflammatory cytokines from lung parenchyma and whole blood and attenuated adhesion molecule expression on granulocytes, thereby attenuating the influx of inflammatory cells into the lung. As chronic inflammation in the respiratory tract is a characteristic of obstructive lung diseases, such as COPD, knowledge of the effects of olodaterol, apart from bronchodilation, is important for a full understanding of the mechanisms underlying its clinical efficacy.

Acknowledgements

The research of EN and PD was supported by a grant from the Boehringer Ingelheim Pharma GmbH & Co. KG.

Author contributions

E. W., I. K. and E. N. performed the research. E. W., L. W., E. N. and P. D. designed the research study. E. W., I. K., M. J. D., E. N., L. W. and P. D. analysed the data. E. W., L. W. and P. D. wrote the paper.

Conflict of interest

E. W., I. K., M. J. D. and L. W. are employees of Boehringer Ingelheim Pharma GmbH & Co. KG.

References

Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M et al. (2013a). The Concise Guide to PHARMAOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459–1581.
The beta-adrenoceptor agonist clenbuterol is a potent inhibitor of muscle relaxation in mouse isolated trachea. Br J Pharmacol 99: 1797–1867.

Henry PJ, Goldie RG (1990). Beta 1-adrenoceptors mediate smooth ex vivo study. Respir Res 9: 47.

Jeffery PK, Venge P, Gizycki MJ, Egerod I, Dahl R, Faurschou P (2002). Effects of salmeterol on mucosal inflammation in asthma: a placebo-controlled study. Eur Respir J 20: 1378–1385.

Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010). Animal research: Reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577–1579.

Maneechosetuswan K, Essifie-Quaye S, Meah S, Kelly C, Kharitonov SA, Adcock IM et al (2005). Formoterol attenuates neutrophilic airway inflammation in asthma. Chest 128: 1936–1942.

Maris NA, van der Sluijs KF, Florquin S, de Vos AF, Pater JM, Jansen HM et al. (2004). Salmeterol, a beta2-receptor agonist, attenuates lipopolysaccharide-induced lung inflammation in mice. Am J Physiol Lung Cell Mol Physiol 286: L1122–L1128.

Maris NA, de Vos AF, Dessing MC, Spek CA, Lutter R, Jansen HM et al. (2005). Anti-inflammatory effects of salmeterol after inhalation of lipopolysaccharide by healthy volunteers. Am J Respir Crit Care Med 172: 878–884.

Masclans JR, Barbera JA, MacNee W, Pavia J, Piera C, Lomena F et al. (1996). Salbutamol reduces pulmonary neutrophil sequestration of platelet-activating factor in humans. Am J Respir Crit Care Med 154: 529–532.

McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573–1576.

Miyamoto M, Tomaki M, Lotvall J, Linden A (2004). Beta-adrenoceptor stimulation and neutrophil accumulation in mouse airways. Eur Respir J 24: 231–237.

van Noord JA, Smeets JJ, Drentth BM, Rascher J, Pivovarovar A, Hamilton AL et al. (2011). 24-hour bronchodilation following a single dose of the novel beta(2)-agonist olodaterol in COPD. Pulm Pharmacol Ther 24: 666–672.

Oddera S, Silvestri M, Lantero S, Sacco O, Rossi GA (1998). Downregulation of the expression of intercellular adhesion molecule (ICAM)-1 on bronchial epithelial cells by fenoterol, a beta(2)-adrenoceptor agonist. J Asthma 35: 401–408.

Oldenburger A, Roscioni SS, Jansen E, Menzen MH, Halayko AJ, Timens W et al. (2012). Anti-inflammatory role of the cAMP effectors Epac and PKA: implications in chronic obstructive pulmonary disease. PLoS ONE 7: e31574.

Pawson AJ, Sharman HE, Faccenda E, Alexander SPH, Benson IM et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098–D1106.

Profta M, Bonanno A, Montalbano AM, Albano GD, Riccobono L, Siena L et al. (2012). beta(2) long-acting and anticholinergic drugs control TGF-beta1-mediated neutrophilic inflammation in COPD. Biochim Biophys Acta 1822: 1079–1089.

Raemdonck K, de Alba J, Birrell MA, Grace M, Maher SA, Irvin CG et al. (2012). A role for sensory nerves in the late asthmatic response. Thorax 67: 19–25.

Shinkai N, Takasuna K, Takayama S (2003). Inhibitory effects of formoterol on lipopolysaccharide-induced premature delivery through modulation of proinflammatory cytokine production in mice. Reproduction 125: 199–203.
Strandberg K, Blidberg K, Sahlander K, Palmberg L, Larsson K (2010). Effect of formoterol and budesonide on chemokine release, chemokine receptor expression and chemotaxis in human neutrophils. Pulm Pharmacol Ther 23: 316–323.

Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A et al. (2013). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 187: 347–365.

Wang J, Nie B, Xiong W, Xu Y (2012). Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis. J Clin Pharm Ther 37: 204–211.

Wollin L, Pieper MP (2010). Tiotropium bromide exerts anti-inflammatory activity in a cigarette smoke mouse model of COPD. Pulm Pharmacol Ther 23: 345–354.

Yoshimura T, Kurita C, Nagao T, Usami E, Nakao T, Watanabe S et al. (1997a). Inhibition of tumor necrosis factor-alpha and interleukin-1-beta production by beta-adrenoceptor agonists from lipopolysaccharide-stimulated human peripheral blood mononuclear cells. Pharmacology 54: 144–152.

Yoshimura T, Kurita C, Nagao T, Usami E, Nakao T, Watanabe S et al. (1997b). Effects of cAMP-phosphodiesterase isozyme inhibitor on cytokine production by lipopolysaccharide-stimulated human peripheral blood mononuclear cells. Gen Pharmacol 29: 633–638.